
In a phase 2 trial, tofacitinib met its safety end point and lowered interferon and cytokine scores in adolescents and adults with Down syndrome.
A low neutrophil count in a child may reflect a mild condition or may be a signal of a serious disorder. Sorting out the difference between the two can avoid complications and make for a better long-term outcome.






